[go: up one dir, main page]

GT200900112A - Tratamiento de los trastornos generalizados del desarrollo - Google Patents

Tratamiento de los trastornos generalizados del desarrollo

Info

Publication number
GT200900112A
GT200900112A GT200900112A GT200900112A GT200900112A GT 200900112 A GT200900112 A GT 200900112A GT 200900112 A GT200900112 A GT 200900112A GT 200900112 A GT200900112 A GT 200900112A GT 200900112 A GT200900112 A GT 200900112A
Authority
GT
Guatemala
Prior art keywords
treatment
development
generalized
disorders
generalized disorders
Prior art date
Application number
GT200900112A
Other languages
English (en)
Inventor
Magali Haas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200900112A publication Critical patent/GT200900112A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION ESTA DIRIGIDA AL USO DE ALGUNOS COMPUESTOS DE CARBAMATO PARA EL TRATAMIENTO DE PACIENTES CON TRASTORNOS GENERALIZADOS DEL DESARROLLO (PDD'S) QUE SON UNA CATEGORIA DE TRASTORNOS NEUROLOGICOS CARACTERIZADOS POR DETERIORO SEVERO Y GENERALIZADO TALES COMO EL AUTISMO.
GT200900112A 2006-10-31 2009-04-30 Tratamiento de los trastornos generalizados del desarrollo GT200900112A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86359506P 2006-10-31 2006-10-31

Publications (1)

Publication Number Publication Date
GT200900112A true GT200900112A (es) 2010-05-18

Family

ID=39145417

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900112A GT200900112A (es) 2006-10-31 2009-04-30 Tratamiento de los trastornos generalizados del desarrollo

Country Status (17)

Country Link
US (1) US20080103199A1 (es)
EP (1) EP2089011A1 (es)
JP (1) JP2010508354A (es)
KR (1) KR20090080105A (es)
CN (1) CN101568333A (es)
AU (1) AU2007313911A1 (es)
BR (1) BRPI0718323A2 (es)
CA (1) CA2667909A1 (es)
CO (1) CO6180427A2 (es)
EA (1) EA200970435A1 (es)
GT (1) GT200900112A (es)
IL (1) IL198488A0 (es)
MX (1) MX2009004798A (es)
NI (1) NI200900074A (es)
NO (1) NO20092019L (es)
WO (1) WO2008054984A1 (es)
ZA (1) ZA200903772B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
WO2010020585A1 (en) * 2008-08-18 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin reuptake inhibitors for the treatment of rett syndrome
DK2601609T3 (en) 2010-08-02 2017-06-06 Population Bio Inc COMPOSITIONS AND METHODS FOR DISCOVERING MUTATIONS CAUSING GENETIC DISORDERS
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
CA2851388C (en) 2011-10-10 2023-11-21 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
DK2773779T3 (da) 2011-11-04 2020-11-23 Population Bio Inc Fremgangsmåder og sammensætninger til diagnosticering, prognose og forebyggelse af neurologiske tilstande
EP2812452B1 (en) 2012-02-09 2020-05-27 Population Bio, Inc. Methods and compositions for screening and treating developmental disorders
BR112015002687A2 (pt) * 2012-08-06 2019-12-17 S1 Biopharma Inc regimes de tratamento
US9976180B2 (en) 2012-09-14 2018-05-22 Population Bio, Inc. Methods for detecting a genetic variation in subjects with parkinsonism
WO2014052855A1 (en) 2012-09-27 2014-04-03 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
US9566261B2 (en) * 2013-03-12 2017-02-14 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for preventing or treating a memory loss-related disease comprising the same
WO2016036403A1 (en) 2014-09-05 2016-03-10 Population Diagnostics Inc. Methods and compositions for inhibiting and treating neurological conditions
EP3556366B1 (en) 2016-12-14 2025-10-22 SK Biopharmaceuticals Co., Ltd. Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2020033700A1 (en) 2018-08-08 2020-02-13 Pml Screening, Llc Mathods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
CN113993523A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗抑郁症和其他各种病症

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ551954A (en) * 2001-02-27 2008-07-31 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating movement disorders
RS51055B (sr) * 2001-02-27 2010-10-31 Ortho-Mcneil Pharmaceutical Inc. Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju neurodegenerativnih poremećaja
ATE324108T1 (de) * 2001-02-27 2006-05-15 Ortho Mcneil Pharm Inc Carbamatverbindungen zur verwendung bei der prävention oder behandlung der bipolaren erkrankung
NZ527991A (en) * 2001-02-27 2005-04-29 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating psychotic disorders
RS51269B (sr) * 2004-09-16 2010-12-31 Janssen Pharmaceutica N.V. Upotreba 2-fenil-1,2-etandiol-(di)karbamata za tretiranje epileptogeneze

Also Published As

Publication number Publication date
AU2007313911A1 (en) 2008-05-08
EA200970435A1 (ru) 2009-10-30
CA2667909A1 (en) 2008-05-08
KR20090080105A (ko) 2009-07-23
NI200900074A (es) 2010-02-01
US20080103199A1 (en) 2008-05-01
WO2008054984A1 (en) 2008-05-08
NO20092019L (no) 2009-06-23
EP2089011A1 (en) 2009-08-19
IL198488A0 (en) 2010-02-17
CO6180427A2 (es) 2010-07-19
BRPI0718323A2 (pt) 2013-11-26
JP2010508354A (ja) 2010-03-18
ZA200903772B (en) 2010-08-25
MX2009004798A (es) 2009-08-12
CN101568333A (zh) 2009-10-28

Similar Documents

Publication Publication Date Title
GT200900112A (es) Tratamiento de los trastornos generalizados del desarrollo
ECSP077275A (es) Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
ECSP12011968A (es) Nuevos compuestos tricíclicos
ECSP034811A (es) Derivados heterocicliloxi-, -tioxi - y - aminobenzazole tales como ligandos 5-hidroxitriptamina-6
SV2011003802A (es) Derivados de triazol utiles para el tratamiento de enfermedades
PA8621901A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
DOP2012000151A (es) Nuevos compuestos triciclicos
ECSP088821A (es) Derivados de tioxantina y su uso como inhibidores de la mpo
ECSP066730A (es) Compuestos y procedimientos para uso
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
ECSP14013221A (es) Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento.
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
GT200700103A (es) Compuestos biciclocarboxiamida sustituidos
ECSP12007795A (es) 1h-quinazolin-2,4-dionas y su uso como ligandos del receptor de ampa
CO6382118A2 (es) Nuevas octahidrociclopenta(c)ciprol-4aminas sustituidas como bloqueantes de los canales de calcio
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.
BRPI0518169A (pt) tiazolil-dihidro-indazóis
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
PA8603001A1 (es) Compuestos utiles para el tratamiento de enfermedades
UY28484A1 (es) Compuestos para el tratamiento de trastornos neurodegenerativos
AR057239A1 (es) Inmunoglobulinas
NI200900073A (es) Compuestos de carbamato para su uso en el tratamiento de la depresión.
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades